-
Product Insights
Angiosarcoma - Drugs In Development, 2024
Empower your strategies with our Angiosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Angiosarcoma is a rare type of cancer that that develops in the inner lining of the blood and lymph vessels and is linked to a gene called POTI. Angiosarcoma appears as a bruise-like lesion that grows over time. Once metastatic, it becomes difficult to treat and the survival rate drops to 12-33%. The Angiosarcoma drugs in development market research report provide comprehensive information...
-
Product Insights
T-Cell Leukemia - Drugs In Development, 2024
Empower your strategies with our T-Cell Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. T-cell leukemia is a rare type of blood cancer that affects T cells, which are white blood cells that help your body fight infection or illness. There are different types of T-cell leukemia, such as large granular lymphocytic leukemia, adult T-cell leukemia/lymphoma, and T-cell prolymphocytic leukemia. These types vary in their symptoms, risk factors, diagnosis, treatment and outlook. T-cell leukemia can be...
-
Product Insights
Adenoid Cystic Carcinoma (ACC) - Drugs In Development, 2024
Empower your strategies with our Adenoid Cystic Carcinoma (ACC) – Drugs In Development, 2024 report and make more profitable business decisions. Adenoid cystic carcinoma (ACC) is a rare and aggressive type of cancer that originates from glandular tissues. It can occur in various parts of the body, but it is most found in the salivary glands of the head and neck region. ACC is characterized by a MYB oncogene activation and a tendency to invade nerves and metastasize to distant organs....
-
Product Insights
Chondrosarcoma - Drugs In Development, 2024
Empower your strategies with our Chondrosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, and changes in urination....
-
Product Insights
Medullary Thyroid Cancer - Drugs In Development, 2024
Empower your strategies with our Medullary Thyroid Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Medullary thyroid cancer (MTC) is a rare and aggressive type of thyroid cancer that originates from the C cells, which produce calcitonin, a hormone that regulates calcium levels in the blood. MTC accounts for 5-10% of all thyroid cancers and can be sporadic or inherited. Sporadic MTC occurs randomly, while inherited MTC is associated with a genetic condition called multiple endocrine...
-
Product Insights
Metastatic Liver Cancer - Drugs In Development, 2024
Empower your strategies with our Metastatic Liver Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic liver cancer is a condition where cancer cells from another part of the body spread to the liver. The liver is a vital organ that performs many functions, such as filtering toxins, producing bile, and storing glycogen. Metastatic liver cancer can affect these functions and cause symptoms such as pain, jaundice, weight loss, and swelling. The most common cancers that...
-
Product Insights
Colon Carcinoma - Drugs In Development, 2024
Empower your strategies with our Colon Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Colon carcinoma is a type of cancer that affects the large intestine, which includes the colon and the rectum. It is one of the most common cancers worldwide and can cause symptoms such as blood in the stool, weight loss, and fatigue. Colon carcinoma usually develops from benign growths called polyps that form on the inner lining of the colon or rectum....
-
Product Insights
Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) - Drugs In Development, 2024
Empower your strategies with our Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) – Drugs In Development, 2024 report and make more profitable business decisions. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare and heterogeneous group of neoplasms that originate from neuroendocrine cells in the gastrointestinal tract and pancreas. These cells produce hormones that regulate various functions in the body. GEP-NETs can be classified as functional or non-functional, depending on whether they secrete excess hormones or not. Functional GEP-NETs can cause various syndromes, such as carcinoid...
-
Product Insights
Muscle Invasive Bladder Cancer (MIBC) - Drugs In Development, 2024
Empower your strategies with our Muscle Invasive Bladder Cancer (MIBC) – Drugs In Development, 2024 report and make more profitable business decisions. Muscle invasive bladder cancer (MIBC) is a type of bladder cancer that has grown into the muscle wall of the bladder, making it more likely to spread to other parts of the body. It accounts for about 25% of bladder cancers and has a poor prognosis. The main risk factor for MIBC is smoking, but other factors such as...
-
Product Insights
Thymic Carcinoma - Drugs In Development, 2024
Empower your strategies with our Thymic Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Thymic carcinoma is a rare and aggressive cancer that originates from the epithelial cells of the thymus, a gland in the chest that produces immune cells. Thymic carcinoma often spreads to other organs and is resistant to chemotherapy. The symptoms may include chest pain, cough, difficulty breathing, and weight loss. The diagnosis is based on imaging tests and biopsy of the tumor...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.